{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:01:29Z","timestamp":1781157689465,"version":"3.54.1"},"reference-count":271,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3503502"],"award-info":[{"award-number":["2023YFC3503502"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010882","name":"Tianjin Municipal Education Commission","doi-asserted-by":"publisher","award":["2024KJ030"],"award-info":[{"award-number":["2024KJ030"]}],"id":[{"id":"10.13039\/501100010882","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>With the expanding identification of target antigens in primary membranous nephropathy (PMN), treatment is shifting from empirical immunosuppression toward mechanism-based precision immunotherapy. Although rituximab (RTX) has substantially improved the management of PMN, a considerable proportion of patients still experience suboptimal response, relapse, or resistance. Accumulating evidence indicates that RTX resistance is a multifactorial process involving anti-drug antibody formation, reduced bioavailability, incomplete depletion of pathogenic B cells within lymphoid compartments, CD20 internalization and degradation, epitope spreading, persistence of autoantibodies against intracellular antigens, and genetic susceptibility. In response, a broad range of mechanism-guided therapeutic strategies is emerging, including next-generation anti-CD20 monoclonal antibodies, agents targeting distinct stages of B-cell differentiation, and advanced immune-engineering approaches such as CAR-T, CAAR-T, CAAR-NK, CAR-Treg, CAR-macrophage therapies, sweeping antibodies, antibody\u2013drug conjugates, and bispecific autoantigen\u2013T-cell engagers. In parallel, interventions targeting aberrant T\u2013B cell crosstalk and complement activation are providing additional therapeutic opportunities for refractory disease. This review systematically summarizes the major pathogenic mechanisms underlying RTX-resistant PMN and integrates the latest advances in mechanism-based therapeutic strategies, with the aim of informing individualized treatment approaches and future translational research for refractory PMN.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1844062","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:48:30Z","timestamp":1781156910000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment strategies for rituximab-resistant primary membranous nephropathy: from resistance mechanisms to emerging therapies"],"prefix":"10.3389","volume":"17","author":[{"given":"Jingjie","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Nephrology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","place":["Tianjin, China"]},{"name":"Department of Nephrology, National Clinical Research Center for Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","place":["Tianjin, China"]},{"name":"Department of Nephrology, National Clinical Research Center for Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","place":["Tianjin, China"]},{"name":"Department of Nephrology, National Clinical Research Center for Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","place":["Tianjin, China"]},{"name":"Department of Nephrology, National Clinical Research Center for Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","place":["Tianjin, China"]},{"name":"Department of Nephrology, National Clinical Research Center for Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primer"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-49379-4_24","article-title":"Secondary membranous glomerulonephritis","volume-title":"Glomerulonephritis","author":"Hotchkiss","year":"2019"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.06.032","article-title":"Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification","volume":"104","author":"Sethi","year":"2023","journal-title":"Kidney Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000769","article-title":"Questions and caveats in antigen-defined membranous nephropathy","volume":"36","author":"Andeen","year":"2025","journal-title":"J Am Soc Nephrol JASN"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.12.011","article-title":"Novel treatments paradigms: membranous nephropathy","volume":"8","author":"JE","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fern\u00e1ndez-Ju\u00e1rez","year":"2021","journal-title":"Kidney Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1480638","article-title":"Efficacy and safety of glucocorticoid combined with cyclophosphamide therapy on membranous nephropathy: a systematic review and meta-analysis","volume":"15","author":"Feng","year":"2024","journal-title":"Front Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12569","article-title":"Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial","volume":"21","author":"Ramachandran","year":"2016","journal-title":"Nephrology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217116","article-title":"Immunosuppressive regimens based on cyclophospamide or calcineurin inhibitors: comparison of their effect in the long term outcome of primary membranous nephropathy","volume":"14","author":"Stangou","year":"2019","journal-title":"PloS One"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.12.035","article-title":"Rituximab in membranous nephropathy","volume":"6","author":"Gauckler","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S195113","article-title":"Clinical efficacy and safety of rituximab in lupus nephritis","volume":"13","author":"Zhong","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000152","article-title":"Risk factors associated with the occurrence of anti-rituximab antibodies in membranous nephropathy","volume":"18","author":"Teisseyre","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859419","article-title":"Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy","volume":"13","author":"Teisseyre","year":"2022","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Boyer-Suavet","year":"2020","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.5858\/2000-124-0921-HAMA","article-title":"Human anti-mouse antibodies","volume":"124","author":"Klee","year":"2000","journal-title":"Arch Pathol Lab Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/art.42811","article-title":"Vitamin D and marine n\u20103 fatty acids for autoimmune disease prevention: outcomes two years after completion of a double\u2010blind, placebo\u2010controlled trial","volume":"76","author":"Costenbader","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.04.059","article-title":"Anti-rituximab antibodies occurrence and clinical outcomes in patients with primary membranous nephropathy","volume":"10","author":"Allinovi","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.12.012","article-title":"Obinutuzumab and ofatumumab are more effective than rituximab in the treatment of membranous nephropathy patients with anti-rituximab antibodies","volume":"10","author":"Teisseyre","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4161\/self.1.4.13904","article-title":"Immunogenicity of protein therapeutics: the key causes, consequences and challenges","volume":"1","author":"Baker","year":"2010","journal-title":"Self\/Nonself"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2009.09.269","article-title":"236-P: The HLA DR\u03b213 residue is associated with the development of human anti-chimeric antibody in some Crohn\u2019s patients treated with infliximab","volume":"70","author":"Magira","year":"2009","journal-title":"Hum Immunol - Hum Immunol"},{"key":"B23","article-title":"Human leukocyte antigens influence the antibody response to hepatitis B vaccine","volume":"14","author":"Jafarzadeh","year":"2015"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000184162.60197.c1","article-title":"Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings","volume":"27","author":"Regazzi","year":"2005","journal-title":"Ther Drug Monit"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01081-3","article-title":"The influence of underlying disease on rituximab pharmacokinetics may be explained by target-mediated drug disposition","volume":"61","author":"Bensalem","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018803587","article-title":"Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy","volume":"53","author":"Fogueri","year":"2019","journal-title":"Ann Pharmacother"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz041","article-title":"Rituximab bioavailability in primary membranous nephropathy","volume":"34","author":"Boyer-Suavet","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738788","article-title":"Rituximab immunomonitoring predicts remission in membranous nephropathy","volume":"12","author":"Teisseyre","year":"2021","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5414\/CNP88FX07","article-title":"Rituximab for the treatment of membranous nephropathy: a single-center experience","volume":"88","author":"Rigler","year":"2017","journal-title":"Clin Nephrol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/ndt\/gfaf127","article-title":"Urinary rituximab loss and rate of treatment failure in membranous nephropathy","volume":"41","author":"Allinovi","year":"2025","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/1372859","article-title":"Kinetics of rituximab excretion into urine and peritoneal fluid in two patients with nephrotic syndrome","volume":"2017","author":"Stahl","year":"2017","journal-title":"Case Rep Nephrol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transplant"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1159\/000516984","article-title":"Membranous nephropathy: it is time to go back to the future","volume":"145","author":"Sabiu","year":"2021","journal-title":"Nephron"},{"key":"B35","doi-asserted-by":"publisher","first-page":"890","DOI":"10.4049\/jimmunol.182.2.890","article-title":"Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to naive B cells","volume":"182","author":"Good","year":"2009","journal-title":"J Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584509","article-title":"Monitoring of the complement system status in patients with B-cell Malignancies treated with rituximab","volume":"11","author":"Felberg","year":"2020","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.3280","article-title":"Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia","volume":"172","author":"Kennedy","year":"2004","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc3961","article-title":"Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia","volume":"13","author":"Crickx","year":"2021","journal-title":"Sci Transl Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-330357","article-title":"Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy","volume":"118","author":"Lim","year":"2011","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/art.39167","article-title":"Internalization of rituximab and the efficiency of B cell depletion in rheumatoid arthritis and systemic lupus erythematosus","volume":"67","author":"Reddy","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(93)90163-F","article-title":"Determinant spreading and the dynamics of the autoimmune T-cell repertoire","volume":"14","author":"Lehmann","year":"1993","journal-title":"Immunol Today"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(96)80012-4","article-title":"Epitope spreading","volume":"8","author":"Vanderlugt","year":"1996","journal-title":"Curr Opin Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.04.019","article-title":"Autoimmunity and oxidatively modified autoantigens","volume":"7","author":"Kurien","year":"2008","journal-title":"Autoimmun Rev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.4.2565","article-title":"A SmD peptide induces better antibody responses to other proteins within the small nuclear ribonucleoprotein complex than to SmD protein via intermolecular epitope spreading1","volume":"178","author":"Deshmukh","year":"2007","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.imlet.2014.11.001","article-title":"B cell epitope spreading: mechanisms and contribution to autoimmune diseases","volume":"163","author":"Cornaby","year":"2015","journal-title":"Immunol Lett"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2007030342","article-title":"Intramolecular epitope spreading in Heymann nephritis","volume":"18","author":"Shah","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J Am Soc Nephrol JASN"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.32","article-title":"THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity","volume":"29","author":"Larsen","year":"2016","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-023-00848-w","article-title":"Lupus-like membranous nephropathy during the postpartum period expressing glomerular antigens exostosin 1\/exostosin 2 and phospholipase A2 receptor: a case report","volume":"13","author":"Miyasaka","year":"2024","journal-title":"CEN Case Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2021.03.013","article-title":"Primary membranous nephropathy with enhanced staining of exostosin 1\/exostosin 2 in the glomeruli: a report of 2 cases","volume":"3","author":"Iwakura","year":"2021","journal-title":"Kidney Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.09.016","article-title":"Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis","volume":"100","author":"Caza","year":"2021","journal-title":"Kidney Int"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00467-008-1009-5","article-title":"Pathophysiological lessons from rare associations of immunological disorders","volume":"24","author":"Ronco","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000962","article-title":"Mapping of phospholipase A2 receptor epitopes in idiopathic membranous nephropathy and clinical relevance of epitope profiles","volume":"37","author":"Liu","year":"2026","journal-title":"J Am Soc Nephrol JASN"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017070734","article-title":"Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy","volume":"29","author":"Seitz-Polski","year":"2018","journal-title":"J Am Soc Nephrol JASN"},{"key":"B55","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1681\/ASN.2019030273","article-title":"Clinical relevance of domain-specific phospholipase A2 receptor 1 antibody levels in patients with membranous nephropathy","volume":"31","author":"Reinhard","year":"2020","journal-title":"J Am Soc Nephrol JASN"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298269","article-title":"Quantitative detection and prognostic value of antibodies against M-type phospholipase A2 receptor and its cysteine-rich ricin domain and C-type lectin domains 1 and 6-7-8 in patients with idiopathic membranous nephropathy","volume":"19","author":"Liu","year":"2024","journal-title":"PloS One"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11791018","article-title":"High-dose rituximab and early remission in PLA2R1-related membranous nephropathy","volume":"14","author":"Seitz-Polski","year":"2019","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"B58","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1053\/j.ajkd.2023.10.013","article-title":"Anti-phospholipase A2 receptor 1 and anti-cysteine rich antibodies, domain recognition and rituximab efficacy in membranous nephropathy: a prospective cohort study","volume":"83","author":"Ruggenenti","year":"2024","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1685738","article-title":"Clinical study of PLA2R epitope spreading for predicting proteinuria remission in primary membranous nephropathy","volume":"16","author":"Cheng","year":"2025","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00412","article-title":"Personalized medicine for PLA2R1-related membranous nephropathy: a multicenter randomized control trial","volume":"7","author":"Brglez","year":"2020","journal-title":"Front Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/prca.201000079","article-title":"In vivo characterization of renal auto-antigens involved in human auto-immune diseases: the case of membranous glomerulonephritis","volume":"5","author":"Murtas","year":"2011","journal-title":"Proteomics Clin Appl"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008121259","article-title":"Autoimmunity in membranous nephropathy targets aldose reductase and SOD2","volume":"21","author":"Prunotto","year":"2010","journal-title":"J Am Soc Nephrol JASN"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2011.05.021","article-title":"Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: alfa-enolase and borderline antigens","volume":"74","author":"Bruschi","year":"2011","journal-title":"J Proteomics"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02170312","article-title":"Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy","volume":"7","author":"Murtas","year":"2012","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02500220","article-title":"Multi-autoantibody signature and clinical outcome in membranous nephropathy","volume":"15","author":"Ghiggeri","year":"2020","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.24815","article-title":"Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies","volume":"5","author":"Passot","year":"2013","journal-title":"mAbs"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ady4877","article-title":"Single-amino acid variants in target epitopes can confer resistance to antibody-based therapies","volume":"17","author":"Marone","year":"2025","journal-title":"Sci Transl Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12882-023-03273-4","article-title":"The value of PLA2R antigen and IgG subclass staining relative to anti-PLA2R seropositivity in the differential diagnosis of membranous nephropathy","volume":"24","author":"Bajcsi","year":"2023","journal-title":"BMC Nephrol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104936","article-title":"The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis","volume":"9","author":"Du","year":"2014","journal-title":"PloS One"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1011678","article-title":"PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy","volume":"364","author":"Debiec","year":"2011","journal-title":"N Engl J Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2015.12.057","article-title":"Phospholipase A2 receptor staining is absent in many kidney biopsies with early-stage membranous glomerulonephritis","volume":"89","author":"Ryan","year":"2016","journal-title":"Kidney Int"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1159\/000431331","article-title":"Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy","volume":"41","author":"Xie","year":"2015","journal-title":"Am J Nephrol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.207","article-title":"Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies","volume":"26","author":"Larsen","year":"2013","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1297107","article-title":"Clinicopathological and prognostic characteristics of idiopathic membranous nephropathy with dual antigen positivity","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1053\/j.ajkd.2025.08.013","article-title":"What\u2019s new in membranous nephropathy and how to incorporate new antigen discoveries into clinical practice: a review","volume":"87","author":"Zand","year":"2026","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00350122","article-title":"Glomerular exostosin as a subtype and activity marker of class 5 lupus nephritis","volume":"17","author":"Wang","year":"2022","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"B79","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/ndt\/gfac058","article-title":"EXT1 and NCAM1-associated membranous lupus nephritis in a cohort of patients undergoing repeat kidney biopsies","volume":"38","author":"Miller","year":"2023","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000061","article-title":"Membranous nephropathy in syphilis is associated with neuron-derived neurotrophic factor","volume":"34","author":"Sethi","year":"2023","journal-title":"J Am Soc Nephrol JASN"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.08.025","article-title":"Contactin 1, a potential new antigen target in membranous nephropathy: a case report","volume":"80","author":"Santoro","year":"2022","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.04.006","article-title":"Proprotein convertase subtilisin\/kexin type 6 (PCSK6) is a likely antigenic target in membranous nephropathy and nonsteroidal anti-inflammatory drug use","volume":"104","author":"Sethi","year":"2023","journal-title":"Kidney Int"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1540694","article-title":"Efficacy and safety of ripertamab for treating primary membranous nephropathy among adults: a multicenter, retrospective, real-world study","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"20567","DOI":"10.1038\/s41598-025-06046-1","article-title":"The efficacy and safety of ripertamab in the treatment of idiopathic membranous nephropathy: a retrospective multicenter cohort study","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.2165\/11203850-000000000-00000","article-title":"Ofatumumab","volume":"70","author":"Sanford","year":"2010","journal-title":"Drugs"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1508624","article-title":"Anti-CD20 monoclonal antibodies: reviewing a revolution","volume":"14","author":"Casan","year":"2018","journal-title":"Hum Vaccines Immunother"},{"key":"B87","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/11539590-000000000-00000","article-title":"New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid Malignancies","volume":"25","author":"Robak","year":"2011","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"key":"B88","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.coche.2014.11.003","article-title":"Overcoming transport barriers for interstitial-, lymphatic-, and lymph node-targeted drug delivery","volume":"7","author":"Thomas","year":"2015","journal-title":"Curr Opin Chem Eng"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01340","article-title":"Imaging mass cytometry and single-cell genomics reveal differential depletion and repletion of B-cell populations following ofatumumab treatment in cynomolgus monkeys","volume":"10","author":"Theil","year":"2019","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-232896","article-title":"Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness","volume":"13","author":"Podest\u00e0","year":"2020","journal-title":"BMJ Case Rep"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1610530","article-title":"Case report: Subcutaneous ofatumumab for patients with immunosuppressant-dependent or ineffective primary membranous nephropathy","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1053\/j.ajkd.2023.08.010","article-title":"Ofatumumab in rituximab-resistant and rituximab-intolerant patients with primary membranous nephropathy: a case series","volume":"83","author":"Podest\u00e0","year":"2024","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"B93","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"mAbs"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000555","article-title":"Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy","volume":"19","author":"Hu","year":"2024","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf026","article-title":"Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy","volume":"18","author":"Su","year":"2025","journal-title":"Clin Kidney J"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-020-00874-2","article-title":"Successful treatment of PLA2R1-antibody positive membranous nephropathy with ocrelizumab","volume":"34","author":"Schmidt","year":"2021","journal-title":"J Nephrol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad041","article-title":"Future landscape for the management of membranous nephropathy","volume":"16","author":"Caravaca-Font\u00e1n","year":"2023","journal-title":"Clin Kidney J"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41467-018-03620-2","article-title":"BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus","volume":"9","author":"Shin","year":"2018","journal-title":"Nat Commun"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000499","article-title":"Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE","volume":"9","author":"Struemper","year":"2022","journal-title":"Lupus Sci Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226051","article-title":"Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways","volume":"84","author":"Moysidou","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B102","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/ndt\/gfz086","article-title":"Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy","volume":"35","author":"Barrett","year":"2020","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.6.3655","article-title":"Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL","volume":"180","author":"Benson","year":"2008","journal-title":"J Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1186\/ar3738","article-title":"Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial","volume":"14","author":"Ginzler","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2510198","article-title":"A phase 3 trial of atacicept in patients with igA nephropathy","volume":"394","author":"Lafayette","year":"2026","journal-title":"N Engl J Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2025.2511761","article-title":"Inhibition of long-lived plasma cells, a critical role for Telitacicept treatment to systemic lupus erythematosus","volume":"47","author":"Zhang","year":"2025","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.9553","article-title":"Single-dose telitacicept therapy for refractory idiopathic membranous nephropathy: A case series","volume":"12","author":"Sun","year":"2024","journal-title":"Clin Case Rep"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/89782","article-title":"TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice","volume":"2","author":"Wang","year":"2001","journal-title":"Nat Immunol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1571616","article-title":"Telitacicept monotherapy for refractory idiopathic membranous nephropathy: a case report and literature review","volume":"12","author":"Chen","year":"2025","journal-title":"Front Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.946727","article-title":"Telitacicept and tacrolimus synergy in managing refractory primary membranous nephropathy: case insights","volume":"26","author":"Huang","year":"2025","journal-title":"Am J Case Rep"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2011.02.009","article-title":"Rituximab resistance","volume":"24","author":"Rezvani","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2024-001296","article-title":"Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study","volume":"12","author":"Chen","year":"2025","journal-title":"Lupus Sci Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2015.1052928","article-title":"A plastic SQSTM1\/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells","volume":"11","author":"Milan","year":"2015","journal-title":"Autophagy"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.04.011","article-title":"Bortezomib plus dexamethasone for rituximab-resistant PLA2R+ membranous nephropathy","volume":"100","author":"Salhi","year":"2021","journal-title":"Kidney Int"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-022-05672-5","article-title":"Aggressive immunotherapy combined with bortezomib and rituximab for membranous nephropathy associated with enzyme replacement therapy in Pompe disease","volume":"38","author":"Sasaki","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.08.036","article-title":"Plasma cell-directed rescue with bortezomib in refractory antiphospholipase A2 receptor-positive membranous nephropathy","volume":"10","author":"Ayub","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"mAbs"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via fc\u03b3 Receptor-mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14263","article-title":"A case of treatment-resistant membranous nephropathy associated with graft versus host disease successfully treated with daratumumab","volume":"26","author":"Benoit","year":"2022","journal-title":"Pediatr Transplant"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04811-0","article-title":"A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome","volume":"36","author":"Dossier","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000772","article-title":"Targeting B cells and plasma cells in glomerular disease","volume":"36","author":"Ahmad","year":"2025","journal-title":"J Am Soc Nephrol JASN"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1006\/clim.1999.4732","article-title":"Bruton\u2019s tyrosine kinase controls a sustained calcium signal essential for B lineage development and function","volume":"91","author":"Rawlings","year":"1999","journal-title":"Clin Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115297","article-title":"Blockade of Bruton\u2019s tyrosine kinase suppresses B cell activation and antibody secretion in systemic lupus erythematosus","volume":"163","author":"Shi","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2023.100377","article-title":"Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report","volume":"20","author":"Turcotte","year":"2023","journal-title":"Leuk Res Rep"},{"key":"B132","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12882-022-02873-w","article-title":"A case report of pre-eclampsia-like endothelial injury in the kidney of an 85-year-old man treated with ibrutinib","volume":"23","author":"Li","year":"2022","journal-title":"BMC Nephrol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-021-01049-7","article-title":"Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell Malignancies","volume":"14","author":"Gu","year":"2021","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01712","article-title":"Discovery of GDC-0853: A potent, selective, and noncovalent bruton\u2019s tyrosine kinase inhibitor in early clinical development","volume":"61","author":"Crawford","year":"2018","journal-title":"J Med Chem"},{"key":"B135","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11095-019-2752-y","article-title":"Population pharmacokinetics, efficacy exposure-response analysis, and model-based meta-analysis of fenebrutinib in subjects with rheumatoid arthritis [corrected","volume":"37","author":"Chan","year":"2020","journal-title":"Pharm Res"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-083122-044829","article-title":"B cell-directed therapy in autoimmunity","volume":"42","author":"Abeles","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00377-1","article-title":"CAR T-cell therapy in autoimmune diseases: where are we and where are we going","volume":"7","author":"Scherlinger","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.06.2128","article-title":"BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis","volume":"84","author":"Hu","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103369","article-title":"CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy","volume":"151","author":"Uppin","year":"2025","journal-title":"J Autoimmun"},{"key":"B140","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.06.2120","article-title":"Effects of different B-cell-depleting strategies on the lymphatic tissue","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.06.2132","article-title":"Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus","volume":"85","author":"Garantziotis","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ircmb.2022.04.007","article-title":"mRNA-based therapies: Preclinical and clinical applications","volume":"372","author":"Qureischi","year":"2022","journal-title":"Int Rev Cell Mol Biol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2023.08.005","article-title":"Chimeric antigen receptor therapy meets mRNA technology","volume":"42","author":"Wu","year":"2024","journal-title":"Trends Biotechnol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.822508","article-title":"Strategies towards antigen-specific treatments for membranous nephropathy","volume":"13","author":"K\u00f6llner","year":"2022","journal-title":"Front Immunol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B150","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1681\/ASN.2013121315","article-title":"Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy","volume":"26","author":"Kao","year":"2015","journal-title":"J Am Soc Nephrol JASN"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017070805","article-title":"The most N-terminal region of THSD7A is the predominant target for autoimmunity in THSD7A-associated membranous nephropathy","volume":"29","author":"Seifert","year":"2018","journal-title":"J Am Soc Nephrol JASN"},{"key":"B152","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.kint.2025.09.028","article-title":"Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells","volume":"109","author":"Altun","year":"2026","journal-title":"Kidney Int"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00235","article-title":"Natural regulators\u201d: NK cells as modulators of T cell immunity","volume":"7","author":"Schuster","year":"2016","journal-title":"Front Immunol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010004","article-title":"Role of IL-10-producing natural killer cells in the regulatory mechanisms of inflammation during systemic infection","volume":"12","author":"Martinez-Espinosa","year":"2021","journal-title":"Biomolecules"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: A promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"B156","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: From CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J Exp Clin Cancer Res CR"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.01.021","article-title":"An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells","volume":"105","author":"Seifert","year":"2024","journal-title":"Kidney Int"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.02.014","article-title":"New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature","volume":"15","author":"Roccatello","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.01.012","article-title":"B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab","volume":"92","author":"Rosenzwajg","year":"2017","journal-title":"Kidney Int"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197015","article-title":"Treg enhancing therapies to treat autoimmune diseases","volume":"21","author":"Eggenhuizen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0120-4","article-title":"Regulatory T cells in autoimmune disease","volume":"19","author":"Dominguez-Villar","year":"2018","journal-title":"Nat Immunol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: Challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2026.02.001","article-title":"CAR-mediated release of IL-10 increases the function of regulatory T cells: Relevance for future clinical application","volume":"34","author":"Saleem","year":"2026","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1235222","article-title":"CAR-T cells and CAR-Tregs targeting conventional type-1 dendritic cell suppress experimental autoimmune encephalomyelitis","volume":"14","author":"Moorman","year":"2023","journal-title":"Front Immunol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00541-3","article-title":"Macrophages and the maintenance of homeostasis","volume":"18","author":"Mosser","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2014.09.020","article-title":"Transglutaminase 2 interacts with syndecan-4 and CD44 at the surface of human macrophages to promote removal of apoptotic cells","volume":"1853","author":"Nadella","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.13201\/j.issn.1004-2806.2022.04.002","article-title":"Levels and clinical significance of serum IL-2, IL-10, TNF-\u03b1 and IFN-\u03b3 in patients with early idiopathic membranous nephropathy","volume":"35","author":"Xiurong","year":"2022","journal-title":"J Clin Hematol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01387-8","article-title":"Targeting inflammation with chimeric antigen receptor macrophages using a signal switch","volume":"9","author":"Cao","year":"2025","journal-title":"Nat BioMed Eng"},{"key":"B171","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13287-023-03277-9","article-title":"Superior protective effects of PGE2 priming mesenchymal stem cells against LPS-induced acute lung injury (ALI) through macrophage immunomodulation","volume":"14","author":"Hezam","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2018.08.002","article-title":"Immunomodulatory effects of mesenchymal stem cells on leukocytes with emphasis on neutrophils","volume":"223","author":"Salami","year":"2018","journal-title":"Immunobiology"},{"key":"B173","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12943-023-01737-7","article-title":"NK cells are never alone: Crosstalk and communication in tumour microenvironments","volume":"22","author":"Zhou","year":"2023","journal-title":"Mol Cancer"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13060843","article-title":"Mesenchymal stem cells as a gene delivery tool: Promise, problems, and prospects","volume":"13","author":"Attia","year":"2021","journal-title":"Pharmaceutics"},{"key":"B175","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41422-020-0354-1","article-title":"Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis","volume":"30","author":"Wu","year":"2020","journal-title":"Cell Res"},{"key":"B176","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s13287-022-02917-w","article-title":"The therapeutic effects of human embryonic stem cells-derived immunity-and-matrix regulatory cells on membranous nephropathy","volume":"13","author":"Zhou","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B177","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13287-022-02839-7","article-title":"Every road leads to Rome: Therapeutic effect and mechanism of the extracellular vesicles of human embryonic stem cell-derived immune and matrix regulatory cells administered to mouse models of pulmonary fibrosis through different routes","volume":"13","author":"Yang","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2022.100389","article-title":"Research progress of stem cell therapy for endometrial injury","volume":"16","author":"Cen","year":"2022","journal-title":"Mater Today Bio"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.735465","article-title":"Regenerative effects of locally or intra-arterially administered BMSCs on the thin endometrium","volume":"10","author":"Guo","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa333","article-title":"Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis","volume":"143","author":"Petrou","year":"2020","journal-title":"Brain J Neurol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00682","article-title":"Unraveling the interaction between FcRn and albumin: Opportunities for design of albumin-based therapeutics","volume":"5","author":"Sand","year":"2014","journal-title":"Front Immunol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063236","article-title":"Engineered monoclonal antibody with novel antigen-sweeping activity in vivo","volume":"8","author":"Igawa","year":"2013","journal-title":"PloS One"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401470","article-title":"Inhibitory Fc\u03b3RIIb-mediated soluble antigen clearance from plasma by a pH-dependent antigen-binding antibody and its enhancement by Fc engineering","volume":"195","author":"Iwayanagi","year":"2015","journal-title":"J Immunol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12392","article-title":"Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation","volume":"270","author":"Igawa","year":"2016","journal-title":"Immunol Rev"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014050502","article-title":"Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy","volume":"26","author":"Fresquet","year":"2015","journal-title":"J Am Soc Nephrol JASN"},{"key":"B186","doi-asserted-by":"publisher","first-page":"e0209509","DOI":"10.1371\/journal.pone.0209509","article-title":"Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody","volume":"13","author":"Sampei","year":"2018","journal-title":"PloS One"},{"key":"B187","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41598-017-01087-7","article-title":"Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases","volume":"7","author":"Fukuzawa","year":"2017","journal-title":"Sci Rep"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.149426","article-title":"Antibody-based targeted protein degradation: Mechanisms, challenges and future directions","volume":"337","author":"Li","year":"2026","journal-title":"Int J Biol Macromol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.123.001084","article-title":"Precision medicine in rheumatic diseases: Unlocking the potential of antibody-drug conjugates","volume":"76","author":"Huang","year":"2024","journal-title":"Pharmacol Rev"},{"key":"B190","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2019.06.001","article-title":"Antibody therapeutics and immunoregulation in cancer and autoimmune disease","volume":"64","author":"Yasunaga","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1172\/JCI124466","article-title":"Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus","volume":"129","author":"Furie","year":"2019","journal-title":"J Clin Invest"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15888","article-title":"A first-in-human study of the novel immunology antibody-drug conjugate, ABBV-3373, in healthy participants","volume":"90","author":"D\u2019Cunha","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1172\/JCI127101","article-title":"A promising approach to targeting type 1 IFN in systemic lupus erythematosus","volume":"129","author":"Chaichian","year":"2019","journal-title":"J Clin Invest"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052505","article-title":"Type I interferons in systemic lupus erythematosus: A journey from bench to bedside","volume":"23","author":"Sim","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1335998","article-title":"Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases","volume":"15","author":"Perico","year":"2024","journal-title":"Front Immunol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2202209119","article-title":"Structure of PLA2R reveals presentation of the dominant membranous nephropathy epitope and an immunogenic patch","volume":"119","author":"Fresquet","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.07.028","article-title":"A comprehensive phenotypic and functional immune analysis unravels circulating anti-phospholipase A2 receptor antibody secreting cells in membranous nephropathy patients","volume":"5","author":"Cantarelli","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-555169","article-title":"A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow","volume":"125","author":"Mei","year":"2015","journal-title":"Blood"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.3390\/kidneydial6010002","article-title":"Membranous nephropathy: Advances in diagnosis and treatment, with an eye on PLA2R1-negative forms","volume":"6","author":"Casiraghi","year":"2026","journal-title":"Kidney Dial"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003224","article-title":"CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game","volume":"187","author":"Long","year":"2011","journal-title":"J Immunol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.10.012","article-title":"Regulatory T-cells in autoimmune diseases: challenges, controversies and--yet--unanswered questions","volume":"14","author":"Grant","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s42003-025-08642-3","article-title":"Multi-omics insights of immune cells in the risk and prognosis of idiopathic membranous nephropathy","volume":"8","author":"Song","year":"2025","journal-title":"Commun Biol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1002\/art.40737","article-title":"Adoptive Treg cell therapy in a patient with systemic lupus erythematosus","volume":"71","author":"Dall\u2019Era","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327075","article-title":"Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis","volume":"72","author":"Voskens","year":"2023","journal-title":"Gut"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltad007","article-title":"Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective","volume":"3","author":"Sakaguchi","year":"2023","journal-title":"Immunother Adv"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061485","article-title":"Engineering strategies to enhance TCR-based adoptive T cell therapy","volume":"9","author":"Rath","year":"2020","journal-title":"Cells"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.33029\/1816-2134-2023-44-6-813-824","article-title":"Cellular technologies in immunotherapy of autoimmune diseases","volume":"44","author":"Fisher","year":"2023","journal-title":"Immunologiya"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222501","article-title":"Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial","volume":"81","author":"Humrich","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B209","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13075-024-03388-5","article-title":"Predictive biomarkers for low-dose IL-2 therapy efficacy in systemic lupus erythematosus: a clinical analysis","volume":"26","author":"Feng","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.41451","article-title":"Efficacy and safety of low-dose interleukin 2 for primary Sj\u00f6gren syndrome: a randomized clinical trial","volume":"5","author":"He","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.574997","article-title":"Th17-immune response in patients with membranous nephropathy is associated with thrombosis and relapses","volume":"11","author":"Cremoni","year":"2020","journal-title":"Front Immunol"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.683330","article-title":"Single-cell profiling reveals transcriptional signatures and cell-cell crosstalk in anti-PLA2R positive idiopathic membranous nephropathy patients","volume":"12","author":"Xu","year":"2021","journal-title":"Front Immunol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-024-01992-w","article-title":"IL-23\/IL-17 in a paradoxical association with primary membranous nephropathy","volume":"47","author":"Kaur","year":"2024","journal-title":"Inflammation"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01777","article-title":"Myeloid-derived suppressor cells promote the progression of primary membranous nephropathy by enhancing Th17 response","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.3390\/jof3040052","article-title":"The role of IL-17 in protection against mucosal Candida infections","volume":"3","author":"Mengesha","year":"2017","journal-title":"J Fungi"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.08.002","article-title":"T helper (Th)-cytokines in the urine of patients with primary glomerulonephritis treated with immunosuppressive drugs: Can they predict outcome","volume":"76","author":"Kalavrizioti","year":"2015","journal-title":"Cytokine"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116583","article-title":"Activation of the IL-6\/STAT3 pathway contributes to the pathogenesis of membranous nephropathy and is a target for Mahuang Fuzi and Shenzhuo Decoction (MFSD) to repair podocyte damage","volume":"174","author":"Zhao","year":"2024","journal-title":"BioMed Pharmacother Biomedecine Pharmacother"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021101384","article-title":"Complement C3a and C3a receptor activation mediates podocyte injuries in the mechanism of primary membranous nephropathy","volume":"33","author":"Gao","year":"2022","journal-title":"J Am Soc Nephrol JASN"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-020-00559-6","article-title":"Membranous nephropathy with thrombotic microangiopathy-like lesions successfully treated with tocilizumab in a patient with idiopathic multicentric Castleman disease","volume":"10","author":"Tosaki","year":"2021","journal-title":"CEN Case Rep"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/4926000","article-title":"A case of Castleman\u2019s disease during the long-term course of membranous nephropathy","volume":"2023","author":"Nakajima","year":"2023","journal-title":"Case Rep Nephrol"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.11.012","article-title":"Suppressive influences of IFN-alpha on IL-17 expression in human CD4+ T cells","volume":"134","author":"Hirohata","year":"2010","journal-title":"Clin Immunol"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.27","article-title":"Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon","volume":"47","author":"Lin","year":"1995","journal-title":"Kidney Int"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr236","article-title":"Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis","volume":"27","author":"Feng","year":"2012","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1002\/art.42482","article-title":"Elevated levels of interferon-\u03b1 act directly on B cells to breach multiple tolerance mechanisms promoting autoantibody production","volume":"75","author":"Ferri","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01037","article-title":"IL-4 and IL-13 receptor signaling from 4PS to insulin receptor substrate 2: there and back again, a historical view","volume":"9","author":"Keegan","year":"2018","journal-title":"Front Immunol"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00415.x","article-title":"Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy","volume":"68","author":"Kuroki","year":"2005","journal-title":"Kidney Int"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15041373","article-title":"Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated T2 comorbidities: one-year real life round","volume":"15","author":"Nettis","year":"2026","journal-title":"J Clin Med"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.09.024","article-title":"Case studies of sustained remission of membranous glomerulonephritis with dupilumab treatment","volume":"9","author":"Kaplan","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B229","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12882-025-04500-w","article-title":"Dupilumab-associated anti-glomerular basement membrane nephritis in a patient with eosinophilic granulomatosis with polyangiitis: a case report","volume":"26","author":"Nakada","year":"2025","journal-title":"BMC Nephrol"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.01.009","article-title":"Exacerbation of IgA nephropathy in a patient receiving dupilumab","volume":"21","author":"Yamamoto","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B231","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev.iy.11.040193.001203","article-title":"The role of the CD28 receptor during T cell responses to antigen","volume":"11","author":"Linsley","year":"1993","journal-title":"Annu Rev Immunol"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.5414\/CNCS108875","article-title":"Costimulation pathway blockade in kidney transplant recipients with de-novo rheumatoid arthritis","volume":"5","author":"Sheta","year":"2017","journal-title":"Clin Nephrol Case Stud"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117982","article-title":"Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation","volume":"95","author":"Cross","year":"1995","journal-title":"J Clin Invest"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1126\/science.7520604","article-title":"Treatment of murine lupus with CTLA4Ig","volume":"265","author":"Finck","year":"1994","journal-title":"Science"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80333-7","article-title":"B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation","volume":"6","author":"Borriello","year":"1997","journal-title":"Immunity"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf030","article-title":"T cell costimulatory blockade ameliorates induction of experimental membranous nephropathy potentially through T-helper 17 cell suppression in the kidney","volume":"40","author":"Chung","year":"2025","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.11.032","article-title":"Establishing a case for anti-complement therapy in membranous nephropathy","volume":"6","author":"Ayoub","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.10.008","article-title":"C5b-9 glomerular deposits are associated with poor renal survival in membranous nephropathy","volume":"8","author":"Teisseyre","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.01.018","article-title":"Proteomic analysis of complement proteins in membranous nephropathy","volume":"5","author":"Ravindran","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B240","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020101395","article-title":"Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy","volume":"32","author":"Al-Rabadi","year":"2021","journal-title":"J Am Soc Nephrol JASN"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281156","article-title":"Contactin-1 links autoimmune neuropathy and membranous glomerulonephritis","volume":"18","author":"Fehmi","year":"2023","journal-title":"PloS One"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.07.039","article-title":"NELL1 is a target antigen in Malignancy-associated membranous nephropathy","volume":"99","author":"Caza","year":"2021","journal-title":"Kidney Int"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13676","article-title":"Proteomics of human glomerulonephritis by laser microdissection and liquid chromatography-tandem mass spectrometry","volume":"25","author":"Kawata","year":"2020","journal-title":"Nephrology"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140453","article-title":"Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy","volume":"131","author":"Haddad","year":"2021","journal-title":"J Clin Invest"},{"key":"B246","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/modpathol.2012.237","article-title":"IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression","volume":"26","author":"Huang","year":"2013","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.07.014","article-title":"The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery","volume":"96","author":"van de Logt","year":"2019","journal-title":"Kidney Int"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.952235","article-title":"The alternative pathway is necessary and sufficient for complement activation by anti-THSD7A autoantibodies, which are predominantly IgG4 in membranous nephropathy","volume":"13","author":"Manral","year":"2022","journal-title":"Front Immunol"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1297352","article-title":"Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway-mediated disorders","volume":"14","author":"Dudler","year":"2023","journal-title":"Front Immunol"},{"key":"B250","article-title":"FAD approves first treatment for adults with complement 3 glomerulopathy, a rare kidney disease, to reduce proteinuria","year":"2025"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14207","article-title":"A first\u2010in\u2010human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF\u201006741086, an anti\u2010tissue factor pathway inhibitor mAb, in healthy volunteers","volume":"16","author":"Cardinal","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.172976","article-title":"C3aR-initiated signaling is a critical mechanism of podocyte injury in membranous nephropathy","volume":"9","author":"Zhang","year":"2024","journal-title":"JCI Insight"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.08.008","article-title":"Avacopan or glucocorticoids for severe antineutrophil cytoplasmic autoantibody\u2013associated rapidly progressive glomerulonephritis","volume":"10","author":"Faguer","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B254","unstructured":"FDA approves ADD drug for adults with a rare form of blood vessel inflammation\n          \n          \n          Silver Spring (MD)\n          U.S. Food and Drug Administration\n          \n          2025"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.11.011","article-title":"Breaking the barrier\u2013glomerular C5b-9 as a prognostic marker in membranous nephropathy","volume":"8","author":"Trinidad","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B256","article-title":"FDA approves first interchangeable biosimilar for two rare diseases","year":"2024"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015101155","article-title":"Phospholipase A2 receptor-related membranous nephropathy and mannan-binding lectin deficiency","volume":"27","author":"Bally","year":"2016","journal-title":"J\u00a0Am Soc Nephrol JASN"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.07.046","article-title":"Intercepting the complement amplification loop through podocyte MC5R signaling ameliorates membranous nephropathy","volume":"33","author":"Liu","year":"2025","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.02.001","article-title":"C3d-targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement","volume":"32","author":"Liu","year":"2024","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12545","article-title":"A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis","volume":"45","author":"M\u00fcller-Deile","year":"2015","journal-title":"Eur J Clin Invest"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015303","article-title":"Plasma exchange and rituximab treatments in primary membranous nephropathy combined with crescentic glomerulonephritis: a case report","volume":"98","author":"Lu","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1159\/000501858","article-title":"Accelerating the depletion of circulating anti-phospholipase A2 receptor antibodies in patients with severe membranous nephropathy: preliminary findings with double filtration plasmapheresis and ofatumumab","volume":"144","author":"Podest\u00e0","year":"2020","journal-title":"Nephron"},{"key":"B263","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/jca.21949","article-title":"Peptide GAM immunoadsorption in anti-PLA2 R positive autoimmune membranous nephropathy. The PRISM trial","volume":"37","author":"Hamilton","year":"2022","journal-title":"J Clin Apheresis"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.05.021","article-title":"Treatment of membranous nephropathy in patients with THSD7A antibodies using immunoadsorption","volume":"74","author":"Weinmann-Menke","year":"2019","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14030249","article-title":"Is there a place for apheresis in the management of idiopathic membranous nephropathy? A report of three cases and literature review","volume":"14","author":"Naciri Bennani","year":"2024","journal-title":"J Pers Med"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315084","article-title":"Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma","volume":"68","author":"Ren","year":"2019","journal-title":"Gut"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2016-0130","article-title":"Roseburia spp.: a marker of health","volume":"12","author":"Tamanai-Shacoori","year":"2017","journal-title":"Future Microbiol"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101320-011829","article-title":"T cell responses to the microbiota","volume":"40","author":"Ivanov","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2564-6","article-title":"Mucosal or systemic microbiota exposures shape the B cell repertoire","volume":"584","author":"Li","year":"2020","journal-title":"Nature"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-020-00560-z","article-title":"Fecal microbiota transplantation for membranous nephropathy","volume":"10","author":"Zhou","year":"2021","journal-title":"CEN Case Rep"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.1159\/000544915","article-title":"Genetically predicted causal relationship between gut microbiota and various kidney diseases","volume":"11","author":"Chen","year":"2025","journal-title":"Kidney Dis Basel Switz"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1844062\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:48:35Z","timestamp":1781156915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1844062\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":271,"alternative-id":["10.3389\/fimmu.2026.1844062"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1844062","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"article-number":"1844062"}}